PRT543 demonstrates a high degree of selectivity for PRMT5 and potent anti-tumor activity and is currently being tested in a phase I human clinical trial for the treatment of advanced solid tumors and hematological malignancies (NCT03886831). This evidence concerns the gene PRMT5 and hematologic disorder.